Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HP-3150 (diclofenac sodium transdermal) pharmacokinetics in lumbar tissues of patients with low back pain
jRCT2080225195Phase 3Completed
- Sponsor
- Hisamitsu Pharmaceutical Co., Inc.
- Start
- May 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, open-label trial of diclofenac in lumbodynia (LBP) (4 arms), sponsored by Hisamitsu Pharmaceutical Co., Inc. Primary endpoints: Diclofenac concentration in lumbar muscle tissue and Diclofenac concentration in lumbar ligament tissue. Started May 2020; status: completed.
02
Drugs
diclofenac
03
Conditions
lumbodynia (LBP)
Beyond the preview
Go deeper on jRCT2080225195.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080225195.